Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
50–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
National Institute on Aging/Alzheimer's Association core clinical criteria for probable AD dementia
Evidence of the AD pathological process, by a positive amyloid assessment either on CSF Aβ1-42 as measured on Elecsys β-Amyloid(1-42) Test System OR amyloid PET scan
AD dementia of moderate severity, as defined by a screening MMSE score of 16-21 points, inclusive, and a CDR-GS of 1 or 2
Availability of a person with sufficient contact with the participant to be able to provide accurate information on the participant's cognitive, behavioral and functional ability
You may not be if
Pregnant or breastfeeding
Inability to tolerate MRI procedures or contraindication to MRI
Contraindication to PET imaging
Residence in a skilled nursing facility
Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or bias the assessment of the clinical or mental status of the participant to a significant degree
Any evidence of a condition other than AD that may affect cognition
Substance abuse within the past 2 years
Use of any experimental therapy within 90 days or 5 half-lives prior to screening, whichever is greater, or any passive immunotherapy against tau
Use of any passive immunotherapy (immunoglobulin) against Aβ, unless the last dose was at least 1 year prior to screening or any active immunotherapy (vaccine) that is under evaluation to prevent or postpone cognitive decline
Any other biologic therapy or previous treatment with medications specifically intended to treat Parkinsonian symptoms or any other non-AD neurodegenerative disorder within 1 year of screening
Systemic immunosuppressive therapy within 12 months of screening through the entire study period
Typical antipsychotic or neuroleptic medication within 6 months of screening
Daily treatment with any of the following classes of medication (except for intermittent short-term use): opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally-acting antihistamine or anticholinergic activity
Stimulant medications, unless the dose has been stable within the 6 months prior to screening and is expected to be stable throughout the study
